RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 3, 2012, Pages 439-449

  Zhai, Feng Xian ^a   Liu, Xiang Fu ^a   Fan, Rui Fang ^a   Long, Zi Jie ^a   Fang, Zhi Gang ^a   Lu, Ying ^a   Zheng, Yong Jiang ^a   Lin, Dong Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 aza 2 deoxycytidine (5 aza CdR); Chronic myeloid leukaemia (CML); Runt related transcription factor 3 (RUNX3); TSA (trichostatin A)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; CASPASE 3; LIPOCORTIN 5; TRANSCRIPTION FACTOR RUNX3; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; AZACITIDINE; HYDROXAMIC ACID; RUNX3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG TARGETING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CPG ISLAND; DRUG EFFECT; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CPG ISLANDS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84859700736     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1113-y     Document Type: Article

References (41)

1. Agirre X, Novo FJ, Calasanz MJ et al (2003a) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 38:201-208 (Pubitemid 37523712)
2. Agirre X, Vizmanos JL, Calasanz MJ et al (2003b) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 22:1070-1072 (Pubitemid 36313150)
3. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159:245-248
4. Balmain A (2002) Cancer: new-age tumor suppressors. Nature 417: 235-237
5. Bangsow C, Rubins N, Glusman G et al (2001) The RUNX3 genesequence structure and regulated expression. Gene 279:221-232 (Pubitemid 33132184)
6. Banin S, Moyal L, Shieh S et al (1998) Enhanced phosphorylation of P53 by ATM in response to DNA damage. Science 281: 1674-1677
7. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis. Trends Genet 16:168-174
8. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21 (Pubitemid 34049633)
9. Bird AP, Wolffe AP (1999) Methylation-induced repression belts, braces, and chromatin. Cell 99:451-454 (Pubitemid 129746827)
10. Chi KC, Margaret HLN (2008) Transcriptional repression of the gene RUNX3/AML2 by the t (8:21) and inv (16) fusion proteins in acute myeloid leukemia. Blood 112:3391-3402
11. Chi XZ, Yang JO, Kim WJ, Ito Y, Bae SC (2005) RUNX3 suppresses gastric epithelial cell growth by inducing P21WAP1/Cip1 expression in cooperation with TGF-b-activated SMAD. Mol Cell Biol 25:8097-8107 (Pubitemid 41263003)
12. Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489-6496 (Pubitemid 37372329)
13. Cordenonsi M et al (2007) Phosphorylation integration of TGF-ß and Ras/MAPK signaling through P53. Science 315:840-843
14. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG (2000) E-cadherin expression is silenced by 5CpG island methylation in acute leukemia. Clin Cancer Res 6:4243-4248
15. Cornelius M, Rebekka G, Claudia M et al (2007) Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. PNAS 104:4594-4599
16. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293-304 (Pubitemid 41437862)
17. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463 (Pubitemid 38715140)
18. el-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of P53 tumor suppression. Cell 75:817-825 (Pubitemid 23346378)
19. Esteller M (2003) Profiling aberrant DNA methylation in hematologicneoplasms: a view from the tip of the iceberg. Clin Immunol 109:80-88 (Pubitemid 37324745)
20. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261-282 (Pubitemid 17122132)
21. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Ito Y (1999) Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cpromoter. J Biol Chem 274:31577-31582
22. Harris CA, Eugane MJ (2001) BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 276:37754-37760
23. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylationassociated inactivation indicates a tumor suppressor role for p15 (INK4B). Cancer Res 56:722-727
24. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837-841 (Pubitemid 27098005)
25. Huang DC, Strasser A (2000) BH3-only proteins-essential initiators of apoptotic cell death. Cell 103:839-842
26. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kudo N, Ito Y (2002) RUNX3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5: 946-954
27. Ito Y, Miyazono K (2003) RUNX transcription factors as key targets of TGF-b superfamily signaling. Curr Opin Genet Dev 13:43-47 (Pubitemid 36143926)
28. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Yeoh KG, Ito Y (2005) RUNX3, a novel tumor suppressor, is highly inactivated in gastric cancer by protein mislocalization. Cancer Res 65:7743-7750 (Pubitemid 41297249)
29. Jahangeer S, Elliott RM, Henneberry RC (1982) b-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun 108: 1434-1440 (Pubitemid 13072819)
30. Kosei I, Anthony C-BL, Manuel S-T et al (2008) RUNX3 attenuates b-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14:226-237
31. Krug U, Ganser A, Koeffler HP (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21:3475-3495 (Pubitemid 34587717)
32. Li QL, Ito K, Sakakura C et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113-124 (Pubitemid 34327521)
33. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
34. Mudit V, Joanna F (2009) Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? Oncol Rep 21(1):3-21
35. Nickerson JA (2001) Experimental observations of a nuclear matrix. J Cell Sci 114:463-474 (Pubitemid 32186105)
36. Okorokov AL, Rubbi CP, Metcalfe S, Milner J (2002) The interaction of P53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 21:356-367 (Pubitemid 34123798)
37. Puig-Kroger A, Corbi A (2006) RUNX3: a new player in myeloid gene expression and immune response. J Cell Biochem 98: 744-756 (Pubitemid 43993393)
38. Quesnel B, Guillerm G, Vereecque R et al (1998) Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990 (Pubitemid 28227550)
39. Sandhya P, Syed AA, Christopher D (2009) Subnuclear targeting of the RUNX3 tumor suppressor and its epigenetic association with mitotic chromosomes. J Cell Physiol 218:473-479
40. Takai D, Jones PA (2003) The CpG island searcher: a new WWW resource. In Silico Biol 3:235-240 (Pubitemid 37493047)
41. Wei D, Gong W, Oh SC et al (2005) Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65:4809-4816 (Pubitemid 40740819)